61 research outputs found
Real-world data of ocrelizumab effects on disability progression; A 2-year follow-up study
No full textIntroduction: Ocrelizumab is an effective treatment in reduc-ing relapse rate and slowing disability progression in the short term.Aims:To evaluate disability progression in people with multiple sclerosis (pwMS) treated with ocrelizumab.Methods: pwMS candidates for ocrelizumab treatment were enrolled in this prospective single-center observational study and followed up for two years. Disability was evaluated with Expanded Disability Status Scale (EDSS), Timed 25 Feet Walk (T25F) test, 9 Hole Peg Test (9HPT), Timed up and Go (TUG) test, and Twelve Item MSWalking Scale (MSWS) survey. First assessments were done before the ocrelizumab initiation and every six months after-ward. Patients with secondary progressive and primary progres-sive MS were analyzed as progressive MS (PMS). A change of %20 in test performance time was considered clinically significant.Results: 107 PMS patients were enrolled. When analyzed sepa-rately, there was no significant difference between baseline and two-year follow-up scores in total EDSS and functional subscores (p>0.05). PMS showed significant worsening in the TUG test (p=0.043) in the first, T25FW (p=0.03) in the second, and MSWS-12 scores in the first (N:99, p:0,006) and the second (N:43 p:0.002) years of evaluation in comparison to baseline results. Of 53 PMS evaluated in the second year, 39 had not shown significant change on 9HPT results, two had improved performance, and 12 had a %20 increase in the test time compared to baseline. Overall 9HPT results did not show a significant change in two-year follow-up (p>0.05).Conclusions: Although ocrelizumab does not show favorable results in the lower extremity functions in the progressive form, it could halt the disability accumulation in the upper extremity in the long term. Disclosure Cavid Baba: nothing to disclose Ergi Kaya: nothing to disclose Sinem Ozcelik: nothing to disclose Asiye Tuba Ozdogar: nothing to disclose Ozge Sagici: nothing to disclose Seda Dastan: nothing to disclose Serkan Ozakbas: nothing to disclose</p
Comparison of late-onset and early-onset people with multiple sclerosis based on cognitive and physical assessments
No full textBackground and aims: Late-onset multiple sclerosis (LOMS) and early-onset multiple sclerosis (EOMS) are less common, and their prognosis can be different. The aim was to assess and compare cognitive functions between patients with LOMS and EOMS. Methods: Patients with LOMS (initial age≥50 years) (n=32) and age-, gender-, and type of MS-matched patients with EOMS (initial age between 15–18 years) (n=125) were assessed with the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery which included the Symbol Digit Modalities Test (SDMT), the California Verbal Learning Test-2 (CVLT2) and the Brief Visuospatial Memory Test-Revised (BVMT-R). The upper extremity function was assessed using the 9 Hole Peg Test (9DPT), Timed 25-Foot Walk Test (T25FW), and Timed up Go (TUG) was used to assess lower extremity function were evaluated. Results: There was no significant difference in disease duration between the two groups. The EDSS score and age were higher in the LOMS group (2.90±2.07 and 60.25±5.42, respectively) compared with EOMS (1.33±1.83 and 25.76±8.98, respectively). Covariates included age and the EDSS score. There was no significant difference between the groups regarding T25FW, TUG, 9HPT, and BICAMS (p>0.05). Conclusion: The cognitive, upper, and lower extremity functions were similar in the two groups. Considering that distribution of gender and the disease durations were similar; these results suggest that the prognosis of EOMS may be worse than expected. Disclosure: Nothing to disclose. </p
Akut Spinal Psödoatetoz
No full textPsödoatetoz, propriyoseptif duysal yolak hasarı sonucu oluşan istemsiz ve özellikle ekstremite distallerinde görülen hiperkinetik bir hareket bozukluğudur. Atetozdan farkı görsel uyaran ortadan kaldırıldığında hareketlerin artmasıdır. Siringomiyeli, B12 vitamin eksikliği, servikal miyelopati, multipl skleroz, miyelit, posterior kord travmaları, tümör veya iskemi psödoatetoz nedenleri arasında yer alır.</p
Which one is more progressive; Primary, or Secondary Progressive Multiple Sclerosis?
No full text[No abstract available
Küçük hücreli akciğer kanseri zemininde gelişen anti-gamma-aminobütirik asit B (anti-GABA-B) reseptör ensefaliti
No full text
Prevalence and related factors of restless legs syndrome in pediatric-onset multiple sclerosis
No full text[No abstract available
Alternative drying of sodium sulfate decahydrate (Na2SO 4·10H2O) with microwave energy
No full textThe anhydrous sodium sulfate (Na2SO4) is produced from the sodium sulfate decahydrate also called mirabilite (Na 2SO4·10H2O) by removing its crystal water. This provides advantages in reducing the transportation costs and in uses in industry. Mirabilite starts to dissolve in its crystal water (i.e. crystal structure decomposes and starts to release its crystal water) above 32.4°C. In industrial applications, to dry off the crystal water, sodium sulfate decahydrate is heated in steam tube rotary or fluidized bed dryers with air above about 150°C. However, drying in rotary dryers is slow due to limitations in mixing and low gas temperatures. Fluidized bed dryers cause dusting and powder formation as a result of attrition caused by collision of particles in the bed. In this investigation, microwave energy has been considered as an alternative approach to solve the problems with current drying processes. With this alternative dehydration process, anhydrous sodium sulfate has been produced successfully from the sodium sulfate decahydrate with no damage to the sodium sulfate crystals. Comparative results of dehydration of sodium sulfate decahydrate in the oven and with microwave energy will be presented as well
The role of pregnancy in relapsing-remitting MS prognosis: A five-year study
No full textIntroduction: Multiple sclerosis (MS) frequently affects women during their reproductive years, leading to growing interest in the interaction between pregnancy and MS progression. The relationship between pregnancy and MS prognosis has been widely studied, yet long-term outcomes remain controversial, with studies presenting conflicting results. Aim: This study aims to assess the long-term impact of pregnancy on MS prognosis by examining relapse rates, Expanded Disability Status Scale (EDSS) scores, and MRI activity over three and five years after delivery. Method: A total of 111 women with MS (wwMS) who delivered either preterm or at full term after MS diagnosis were retrospectively studied. The participants were grouped into those who experienced no relapses during pregnancy (NRG) and those who did (RG). A control group of 85 non-pregnant wwMS (NPG) with matched demographic and clinical characteristics was included for comparative analysis. Clinical data such as relapse rates, EDSS scores, and MRI findings were collected and analyzed statistically to determine the potential impact of pregnancy on MS. Result: Of the women who delivered post-MS diagnosis, 11 experienced relapses during pregnancy. There were no significant differences between the three groups regarding prepregnancy annualized relapse rate, EDSS scores, age at diagnosis, age at pregnancy, oligoclonal band positivity, first symptom localization, or disease-modifying therapy use (p > 0.05). Both the NRG and RG groups experienced significantly more relapses compared to the NPG group during the first three and five years post-delivery (p < 0.05). Additionally, the RG group had a higher relapse rate in the third year after delivery compared to the NRG group (p < 0.05). Conclusion: Having a delivery after an MS diagnosis is associated with increased relapse activity, particularly within the first three years postpartum. However, this heightened relapse activity does not appear to contribute to long-term disability accumulation and MRI activity in wwMS. These findings support the importance of individualized postpartum monitoring
- …
